Apolipoprotein E isoprotein-specific interactions with tissue plasminogen activator

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1689, Issue 3, 2004, Pages 244-251

  Biehle, Susan J ^a   Carrozzella, Janice ^a   Shukla, Rakesh ^b   Popplewell, Jonathan ^c   Swann, Marcus ^c   Freeman, Neville ^c   Clark, Joseph F ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Farfield Sensors Ltd   (United Kingdom)

Author keywords

Apo E; Apolipoprotein E; apolipoprotein E; CD; DPI; dual polarization interferometry; Dual polarization interferometry; Mechanism; Protein protein interaction; recombinant tissue plasminogen activator; Thrombolysis; Tissue plasminogen activator; tPA

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOTTING; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; IMMOBILIZATION; INTERFEROMETRY; MOLECULAR INTERACTION; PERFUSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION;

APOLIPOPROTEINS E; HUMANS; PROTEIN BINDING; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3342890658     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2004.04.004     Document Type: Article

References (48)

1. Corder E., Sanders A., Strittmatter W. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923
2. Payami I., Montee K., Kaye J. Alzheimer's disease, apolipoprotein E4 and gender. JAMA. 271:1994;1316-1317
3. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Verkkoneimi A., Niinisto L., Halonen P., Kontula K. Apolipoprotein E, demenitia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333:1995;1242-1247
4. Broderick J., Lu M., Jackson C., Pancioli A., Tilley B.C., Fagan S.C., Kothari R., Levine S.R., Marler J.R., Lyden P.D., E.C.H. Jr., Brott T., Grotta J.C. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann. Neurol. 49:2001;736-744
5. Corder E., Sanders A., Risch N. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat. Genet. 7:1994;180-184
6. Teter B., Raber J., Nathan B., Crutcher K.A. The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J. Alzheimer's Dis. 4:2002;155-163
7. Tolar M., Marques M.A., Harmony J.A., Crutcher K.A. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 17:1997;5678-5686
8. Tolar M., Keller J.N., Chan S., Mattson M.P., Marques M.A., Crutcher K.A. Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 19:1999;7100-7110
9. Alberts M., Graffafninno C., McClenny C. Effects of apoE genotype and age on survival after intracerebral hemorrhage. Stroke. 27:1996;183
10. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155:2002;487-495
11. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J., Babaey S., Yehuda A., Groswasser Z. Apolipoprotein E-e4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 52:1999;244-248
12. Leung C.H., Poon W.S., Yu L.M., Wong G.K., Ng H.K. Apolipoprotein e genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke. 33:2002;548-552
13. Lynch J.R., Pineda J.A., Morgan D., Zhang L., Warner D.S., Benveniste H., Laskowitz D.T. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann. Neurol. 51:2002;113-117
14. Mamotte C.D.S., Burke V., Taylor R.R., Bockxmeer F.M.v. Evidence of reduced coronary artery disease risk for apolipoprotein E2/3 heterozygotes. Eur. J. Intern. Med. 13:2002;250-255
15. Sorbi S., Namias B., Piacentini S., Repice A., Latottaca S., Forleo P., Amaducci L. ApoE as a prognostic factor for post-traumatic coma. Nat. Med. 1:1995;852
16. Weir C.J., McCarron M.O., Muir K.W., Dyker A.G., Bone I., Lees K.R., Nicoll J.A. Apolipoprotein E genotype, coagulation, and survival following acute stroke. Neurology. 57:2001;1097-1100
17. Teasdale G., Nicoll J., Murray G., Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury L. Lancet. 350:1997;1069-1071
18. Peters-Libeu C.A., Lund-Katz S., Phillips M.C., Wehrli S., Hernaiz M.J., Capila I., Linhardt R.J., Raffai R.L., Newhouse Y.M., Zhou F., Weisgraber K.H. New insights into the heparan sulfate proteoglycan-binding. Activity of apolipoprotein E. J. Biol. Chem. 276:2001;39138-39144
19. Bazin H.G., Marques M.A., Owens A.P. III, Linhardt R.J., Crutcher K.A. Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry. 41:2002;8203-8211
20. Dong J., Peters-Libeu C.A., Weisgraber K.H., Segelke B.W., Rupp B., Capila I., Hernaiz M.J., LeBrun L.A., Linhardt R.J. Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry. 40:2001;2826-2834
21. Paka L., Kako Y., Obunike J.C., Pillarisetti S. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein e. J. Biol. Chem. 274:1999;4816-4823
22. del Zoppo G.J. Thrombolytic therapy in the treatment of stroke. Drugs. 54(Suppl. 3):1997;90-98. (discussion 98-99)
23. Clark J.F., Huri D.A., Carrozzella J., Jauch E.C., Mehta P., Heaton D., Biehle S.J., Broderick J.P. Isoforms of apolipoprotein E can modulate tPA-induced clot lysis in vitro. Front. Biosci. 7:2002;163-168
24. Cross G., Ren Y., Freeman N. Young's Fringes from vertically integrated slab waveguides: applications to humidity sensing. Appl. Phys. 86:1999;6483-6499
25. Cross G.H., Reeves A.A., Brand S., Popplewell J.F., Peel L.L., Swann M.J., Freeman N.J. A new quantitative optical biosensor for protein characterisation. Biosens. Bioelectron. 19:2003;383-390
26. Cross G.H., Reeves A.A., Brand S., Swann M.J., Peel L.L., Freeman N.J., Lu J.R. The metrics of surface adsorbed small molecules on the Young's fringe dual-slab waveguide interferometer. J. Phys., D, Appl. Phys. 37:2004;74-80
27. Crowell K.J., Franzin C.M., Koltay A., Lee S., Lucchese A.M., Snyder B.C., Marassi F.M. Expression and characterization of the FXYD ion transport regulators for NMR structural studies in lipid micelles and lipid bilayers. Biochim. Biophys. Acta. 1645:2003;15-21
28. Neidigh J.W., Andersen N.H. Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle. Biopolymers. 65:2002;354-361
29. Yu K., Park K., Kang S.W., Shin S.Y., Hahm K.S., Kim Y. Solution structure of a cathelicidin-derived antimicrobial peptide, CRAMP as determined by NMR spectroscopy. J. Pept. Res. 60:2002;1-9
30. Milliken G.A., Johnson D.E. Nonreplicated Experiments. 1989;7-12 Chapman & Hall, NY
31. Greenfield N.J. Methods to estimate the conformation of proteins and polypeptides from circular dichroism data. Anal. Biochem. 235:1996;1-10
32. Marler J.R., Tilley B.C., Lu M., Brott T.G., Lyden P.D., Grotta J.C., Broderick J.P., Levine S.R., Frankel M.P., Horowitz S.H., Haley E.C., Lewandowski C.A., Kwiatkowski T.P. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 55:2000;1649-1655
33. Levy D.E., Brott T.G., Haley E.C., Marler J.R., Sheppard G.L., Barsan W., Broderick J.P. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 25:1994
34. Broderick J.P., Lu M., Kothari R., Levine S.R., Lyden P.D., Haley E.C., Brott T.G., Grotta J.C., Tilley B.C., Marler J.R., Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 31:2000;2335-2341
35. Broderick J., Brott T., Kothari R., Miller R., Khoury J., Pancioli A., Gebel J., Mills D., Minneci L., Shukla R. The greater Cincinnati/Northern Kentucky stroke study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 29:1998;415-421
36. Morrow J.A., Arnold K.S., Weisgraber K.H. Functional characterization of apolipoprotein E isoforms overexpressed in escherichia coli. Protein Expr. Purif. 16:1999;224-230
37. Acharya P., Segall M.L., Zaiou M., Morrow J.A., Weisgraber K.H., Phillips M.C., Lund-Katz S., Snow J. Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Biochim. Biophys. Acta. 1584:2002;9-19
38. Waterhous D.V., Johnson W.C.J. Importance of environment in determining secondary structure in proteins. Biochemistry. 33:1994;2121-2128
39. Wang G., Pierens G.K., Treleaven W.D., Sparrow J.T., Cushley R.J. Conformations of human apolipoprotein E(263-286) and E(267-289) in aqueous solutions of sodium dodecyl sulfate by CD and 1 H NMR. Biochemistry. 35:1996;10358-10366
40. a. Biochemistry. 41:2002;5675-5684
41. Dillon P.F., Clark J.F. The theory of diazymes and functional coupling of pyruvate kinase and creatine kinase. J. Theor. Biol. 143:1990;275-284
42. Drouet B., Fifre A., Pincon-Raymond M., Vandekerckhove J., Rosseneu M., Gueant J.L., Chambaz J., Pillot T. ApoE protects cortical neurons against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J. Neurochem. 76:2001;117-127
43. Horie Y., Fazio S., Westerlund J.R., Weisgraber K.H., Rall S.C. Jr. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267:1992;1962-1968
44. Marques M.A., Tolar M., Harmony J.A., Crutcher K.A. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. NeuroReport. 7:1996;2529-2532
45. Tolar M., Marques M.A., Harmony J.A.K., Crutcher K.A. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 17:1997;5678-5686
46. Melchor J.P., Pawlak R., Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J. Neurosci. 23:2003;8867-8871
47. Aleshkov S., Fa M., Karolin J., Strandberg L., Johansson L.B.A., Wilczynska M., Ny T. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. J. Biol. Chem. 271:1996;21231-21238
48. Werner F., Razzaq T., Ellis V. Tissue plasminogen activator binds to human vascular smooth muscle cells by a novel mechanism. J. Biol. Chem. 274:1999;21555-21561